Hp23 use of anti-reflux medication after anti-reflux surgery.

Hp23 use of anti-reflux medication after anti-reflux surgery. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hp23 use of anti-reflux medication after anti-reflux surgery. Abstract Text:

B P L Wijnhoven,C J Lally,J J Kelly,J C Myers,D I Watson,

Purpose It is thought that a substantial number of patients who undergo anti-reflux surgery use anti-reflux medication post operatively, despite no objective evidence of reflux. This study aims to determine the prevalence and underlying reasons for anti-reflux medication usage in patients after anti-reflux surgery. Methodology A questionnaire (13 questions) on the usage of anti-reflux medication was sent to 1016 patients from a prospective database of anti-reflux surgery patients. Results 852 patients (84%), (437 males & 415 females with a mean age 58 yrs) returned the questionnaire. Mean follow up was 5.9 yrs after surgery. A single or combination of medications was being taken by 319 patients (37%): 82% proton pump inhibitors, 9% H2-blockers and 34% antacids. 54 patients (18%) had never stopped taking medication, whereas 261 patients (82%) re-started medication at a mean of 2.4 yrs after surgery. Persistent or return of the same or different symptoms was the reason for taking medication by the vast majority (85%), whereas 15% were asymptomatic or had other reasons for medication use. A response of symptoms to the medication occurred for 30% of the patients, whereas 64% noticed some improvement. Postoperative 24-hour pH studies (while off medication) were abnormal in 17/62 patients (27%) on medication and in 5/73 patients (6%) not taking medication. Conclusions Anti-reflux medication is frequently taken by patients for symptoms after surgery, despite normal pH profiles in the majority. Strategies need to be employed to lower the inappropriate use of medications after surgery and to further evaluate the mechanisms underlying postoperative symptoms, which are non-responsive to anti-reflux medication.

Hp23 use of anti-reflux medication after anti-reflux surgery. Publishing Authors By Initials

BP Wijnhoven,CJ Lally,JJ Kelly,JC Myers,DI Watson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Hp23 use of anti-reflux medication after anti-reflux surgery. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: ANZ journal of surgery

VOLUME: 77 Suppl 1

Page Numbers: A45

Journal Abbreviation:

ISSN: 1445-1433

DAY: 10

MONTH: May

YEAR: 2007

Hp23 use of anti-reflux medication after anti-reflux surgery. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101086634

Hp23 use of anti-reflux medication after anti-reflux surgery. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Hp23 use of anti-reflux medication after anti-reflux surgery. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Hp23 use of anti-reflux medication after anti-reflux surgery.

AFFILIATION: Flinders University Department of Surgery, South Australia, Australia.

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: ANZ J Surg

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hp23 use of anti-reflux medication after anti-reflux surgery Related Publications

• A specific dileucine motif is required for the GGA-dependent entry of newly synthesized insulin-responsive aminopeptidase into the insulin-responsive compartment.
• Advancing quality of urinary incontinence evaluation and treatment in nursing homes through translational research.
• Assessing acrosomal status of bovine sperm using fluoresceinated lectins.
• Characterization of epithelial cell shedding from human small intestine.
• Clinical report: Recovery of a degenerating 14-day embryo in the uterine flush of a mare 7 days after ovulation.
• Current status of newborn screening: decision-making about the conditions to include in screening programs.
• Distraction osteogenesis.
• Do mares possess an intracellular endometrial inhibitor of prostaglandin synthesis during early pregnancy?
• Effect of bone morphogenetic proteins 2 and 7 on septal chondrocytes in alginate.
• Health seeking behavior by families of children suspected to have malaria in Kabale: Uganda.
• Histiocytic sarcoma of the spleen in flat-coated retrievers with regenerative anaemia and hypoproteinaemia.
• Hp19 re-operation for Dysphagia after cardiomyotomy for achalasia.
• Hp23 use of anti-reflux medication after anti-reflux surgery.
• Hp33p laparoscopic anti-reflux surgery in the elderly.
• Human Papillomavirus: Confronting the Epidemic-A Urologist's Perspective.
• Lowering levels of lipids and homocysteine.
• Molecular mechanisms of megakaryopoiesis.
• Paradoxical embolism secondary to ovarian carcinoma resulting in stroke.
• Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer.
• Rac-1 and IQGAP are potential regulators of E-cadherin-catenin interactions during murine preimplantation development.
• Screening for colorectal cancer using the faecal occult blood test, Hemoccult.
• Single- versus dual-process models of lexical decision performance: insights from response time distributional analysis.
• Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.
• Stroke prevention in atrial fibrillation: antiplatelet therapy revisited.
• The effect of buffer osmolality on the survival of cat (Felis catus ) spermatozoa at 5 degrees C.
• The effect of high and low dose Theileria parva infection on the reproductive function of Boran/Friesian heifers.
• The effect of transcervical uterine manipulations on establishment of uterine infection in mares under the influence of progesterone.
• The effects of low level of feeding on response to synchronization of estrus, ovulation rate and embryo loss in goats.
• Understanding the impact of stigma on people with mental illness.
• von Willebrand factor mediates platelet spreading through glycoprotein Ib and alpha(IIb)beta3 in the presence of botrocetin and ristocetin, respectively.